Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial.

Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial. - STAR study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015175

Enrollment

120

Registered

2014-09-17

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Subcutaneous Tocilizumab 162mg every other week. Subcutaneous Abatacept 125mg every week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.20 years or older at registration. 2.Rheumatoid arthritis who fulfill the ACR/EULAR 2010 classification criteria. 3.Patients with positive anti-CCP antibodies. 4.Patients with methotrexate insufficient active rheumatoid arthritis. 5.Patients who gave a written informed consent. 6.Patients with RA duration less than 2 years.

Exclusion criteria

Exclusion criteria: 1.Past history of hypersensitivity to Abatacept or Tocilizumab. 2.Serious infection. 3.Active tuberculosis. 4.Lymphocytes count less than 500/microlitter. 5.Past history of infection of HCV, HBV, HIV, or HTLV-1. 6.History of TNF inhibitor administration within three months at registration. 7.An inappropriate case for the study based on the assessment by the doctor.

Design outcomes

Primary

Measure	Time frame
Improvement of HAQ and CDAI remission rate at 52 weeks.	—

Countries

Japan

Contacts

Public ContactMamiko Shimizu

St.Marianna University School of Medicine Division of Rheumatology, Department of Internal Medicine

mamiko.shimizu@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026